Pluristem Therapeutics (PSTI) – FDA
-
Pluristem Therapeutics (PSTI) Reports Phase III Study of Muscle Regeneration Did Not Meet Primary Endpoint
-
Pluristem Therapeutics (PSTI) Reports PLX-R18 Hematology Phase I Study Results Showing Increase in All Blood Lines and Reduction in Blood Transfusions
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to PSTI Stock Lookup